ArticleWorld journal of gastroenterology2009
Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Therapeutic effects of silibinin in preclinical animal models of gastrointestinal cancers: a systematic review and meta‑analysis.BMC cancer · 2026Pooled it
- Investigating the Epigenetic Therapeutic Potential of Natural Compounds in Cancer.International journal of molecular sciences · 2025Review
- The Role of HSP90 and TRAP1 Targets on Treatment in Hepatocellular Carcinoma.Molecular biotechnology · 2025Review
- A Silibinin-Poly(ε-Caprolactone) Conjugate as an Enhanced Anticancer Agent.Macromolecular bioscience · 2025Article
- A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.Frontiers in pharmacology · 2024Review
- Kaempferide exhibits an anticancer effect against hepatocellular carcinoma in vitro and in vivo.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Silibinin inhibits epithelial‑mesenchymal transition of renal cell carcinoma through autophagy‑dependent Wnt/β‑catenin signaling.International journal of molecular medicine · 2020Article
- Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science.Cancer medicine · 2019Review
- Flavonoids Effects on Hepatocellular Carcinoma in Murine Models: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.Journal of biosciences · 2017Article
- A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.Molecules (Basel, Switzerland) · 2016Article
- Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.World journal of gastroenterology · 2016Review
- Botanicals and Their Bioactive Phytochemicals for Women's Health.Pharmacological reviews · 2016Review
- Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells.World journal of gastroenterology · 2015Article
- Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.BioMed research international · 2015Review
- Epigenetic activities of flavonoids in the prevention and treatment of cancer.Clinical epigenetics · 2015Article
- Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer.Journal of medicinal food · 2013Article
- Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.The AAPS journal · 2013Review
- Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells.Oncology letters · 2013Article
- Perioperative polyphenon E- and siliphos-inhibited colorectal tumor growth and metastases without impairment of gastric or abdominal wound healing in mouse models.Surgical endoscopy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the in vivo effects and mechanisms of silibinin on the growth of hepatocellular carcinoma (HCC) xenografts in nude mice.
methodsNude mice bearing HuH7 xenografts were used to assess the anti-HCC effects and mechanisms of silibinin.
resultsSilibinin resulted in a potent dose-dependent reduction of HuH7 xenografts in association with a significant decrease in Ki-67 and alpha-fetoprotein production, nuclear NF-kappaB content, polo-like kinase 1, Rb phosphorylation, and E2F1/DP1 complex, but increased p27/CDK4 complex and checkpoint kinase 1 expression, suggesting that the in vivo effects of silibinin are mediated by inhibiting G1-S transition of the cell cycle. Silibinin-induced apoptosis of HuH7 xenografts was associated with inhibited survivin phosphorylation. Silibinin-reduced growth of HuH7 xenografts was associated with decreased p-ERK, increased PTEN expression and the activity of silibinin was correlated with decreased p-Akt production, indicating involvement of PTEN/PI(3)K/Akt and ERK pathways in its in vivo anti-HCC effects. Silibinin-reduced growth of HuH7 xenografts was also associated with a significant increase in AC-H3 and AC-H4 expression and the production of superoxide dismutase (SOD)-1.
conclusionSilibinin reduces HCC xenograft growth through the inhibition of cell proliferation, cell cycle progression and PTEN/P-Akt and ERK signaling, inducing cell apoptosis, and increasing histone acetylation and SOD-1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.